Search

Your search keyword '"intraperitoneal xenograft models"' showing total 2 results
Start Over Descriptor "intraperitoneal xenograft models"
2 results on '"intraperitoneal xenograft models"'

1. Pharmacokinetic evaluation and antitumor potency of liposomal nanoparticle encapsulated cisplatin targeted to CD24-positive cells in ovarian cancer.

Author

Ashihara, Keisuke, Terai, Yoshito, Tanaka, Tomohito, Tanaka, Yoshimichi, Fujiwara, Satoe, Maeda, Kazuya, Tunetoh, Satoshi, Sasaki, Hiroshi, Hayashi, Masami, and Ohmichi, Masahide

Subjects
*OVARIAN cancer, *CANCER cells, *CISPLATIN, *TREATMENT effectiveness, *DRUG delivery systems, *THERAPEUTICS
Abstract

CD24, which is upregulated in several human malignancies, is related to Epithelial-mesenchymal-transition (EMT) and has characteristics of cancer stem-like cells, especially in cisplatin-resistant ovarian carcinoma cells. Drug delivery systems represent a promising therapeutic approach for diseases with treatment resistance, and the present study investigated a novel CD24-targeted drug delivery system for advanced ovarian carcinoma. We produced liposomal cisplatin with a red fluorescent substance - cyanine 5.5 (GL-CDDP-Cy5.5). In order to target CD24-positive cells, an anti-CD24 monoclonal antibody was modified to the above drug (CD24-GL-CDDP-Cy5.5). Specific uptake of CD24-GL-CDDP-Cy5.5 was confirmed using a therapeutically resistant ovarian cancer cell line, Caov-3 cells. Antitumor effects of CD24-GL-CDDP-Cy5.5 were then evaluated in Caov-3 ×enograft mice. CD24-GL-CDDP-Cy5.5 showed more specific uptake by flow cytometry than GL-CDDP-Cy5.5. In xenograft mice, GL-CDDP-Cy5.5 and CD24-GL-CDDP-Cy5.5 treatment had significantly higher platinum concentration in disseminated tumor cells than cisplatin (P<0.05). Moreover, CD24-GL-CDDP-Cy5.5 suppressed tumor growth and prolonged survival time compared with other treatments. Median survival times of the control, cisplatin, GL-CDDP-Cy5.5 and CD24-GL-CDDP-Cy5.5 groups were 37, 36, 46 and 54 days after inoculation, respectively. Immunohistochemical analysis showed that CD24-GL-CDDP-Cy5.5 treatment, compared with GL-CDDP-Cy5.5, decreased the number of CD24-positive cells and suppressed the EMT phenomenon significantly (P<0.05). The present study demonstrated that CD24-GL-CDDP-Cy5.5, compared with other treatments, improved therapeutic efficacy. The present results suggested the potential for targeting anticancer therapeutics for CD24-positive cells to prevent disease progression. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

2. Pharmacokinetic evaluation and antitumor potency of liposomal nanoparticle encapsulated cisplatin targeted to CD24-positive cells in ovarian cancer

Author

Masahide Ohmichi, Satoe Fujiwara, Yoshimichi Tanaka, Keisuke Ashihara, Satoshi Tunetoh, Yoshito Terai, Masami Hayashi, Hiroshi Sasaki, Tomohito Tanaka, and Kazuya Maeda

Subjects
0301 basic medicine, inorganic chemicals, Cancer Research, platinum concentration, DDS, Flow cytometry, 03 medical and health sciences, 0302 clinical medicine, Ovarian carcinoma, medicine, skin and connective tissue diseases, neoplasms, CD24, Cisplatin, medicine.diagnostic_test, Oncogene, business.industry, technology, industry, and agriculture, EMT, Cancer, Articles, intraperitoneal xenograft models, Cell cycle, medicine.disease, platinum resistance, female genital diseases and pregnancy complications, 030104 developmental biology, ovarian cancer, Oncology, 030220 oncology & carcinogenesis, Drug delivery, drug delivery, Cancer research, Ovarian cancer, business, medicine.drug
Abstract

CD24, which is upregulated in several human malignancies, is related to Epithelial‑mesenchymal‑transition (EMT) and has characteristics of cancer stem‑like cells, especially in cisplatin‑resistant ovarian carcinoma cells. Drug delivery systems represent a promising therapeutic approach for diseases with treatment resistance, and the present study investigated a novel CD24‑targeted drug delivery system for advanced ovarian carcinoma. We produced liposomal cisplatin with a red fluorescent substance ‑ cyanine 5.5 (GL‑CDDP‑Cy5.5). In order to target CD24‑positive cells, an anti‑CD24 monoclonal antibody was modified to the above drug (CD24‑GL‑CDDP‑Cy5.5). Specific uptake of CD24‑GL‑CDDP‑Cy5.5 was confirmed using a therapeutically resistant ovarian cancer cell line, Caov‑3 cells. Antitumor effects of CD24‑GL‑CDDP‑Cy5.5 were then evaluated in Caov‑3 xenograft mice. CD24‑GL‑CDDP‑Cy5.5 showed more specific uptake by flow cytometry than GL‑CDDP‑Cy5.5. In xenograft mice, GL‑CDDP‑Cy5.5 and CD24‑GL‑CDDP‑Cy5.5 treatment had significantly higher platinum concentration in disseminated tumor cells than cisplatin (P

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results